公开(公告)号：US20200155625A1

公开(公告)日：2020-05-21

申请号：US16616146

申请日：2018-05-24

Applicant: EpicentRx, Inc.

Inventor： Christopher Larson ,  Tony R. Reid ,  Bryan T. Oronsky

IPC: A61K35/761 ,  C12N7/00 ,  C12N15/86 ,  A61K39/395 ,  A61P35/00

Abstract: The invention relates to a recombinant adenovirus that expresses endostatin, angiostatin, or a combination of endostatin and angiostatin. The invention also relates to method of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a combination of (i) a recombinant adenovirus and (ii) an anti-angiogenic agent to treat the cancer in the subject.

公开(公告)号：US20190352669A1

公开(公告)日：2019-11-21

申请号：US16482049

申请日：2018-01-30

Applicant: EpicentRx, Inc.

Inventor： Tony R. Reid ,  Bryan T. Oronsky ,  Farah Hedjran ,  Christopher Larson

IPC: C12N15/86 ,  A61K35/761

Abstract: The invention provides, e.g., a recombinant virus comprising (i) a modified TATA box-based promoter, and/or (ii) a modified CAAT box-based promoter operably linked to a gene, wherein the modified TATA box-based promoter and/or modified CAAT box-based promoter lacks a functional TATA box and/or CAAT box and permit selective expression of the gene in a hyperproliferative cell. The recombinant viruses can be used to treat cell proliferative diseases and disorders, including certain forms of cancer.

公开(公告)号：US12280123B2

公开(公告)日：2025-04-22

申请号：US17575488

申请日：2022-01-13

Applicant: EpicentRx, Inc.

Inventor： Christopher Larson ,  Bryan Oronsky ,  Tony R. Reid

IPC: A61K35/761 ,  A61K47/68 ,  A61K47/69 ,  A61K48/00 ,  A61P35/00 ,  C12N7/02 ,  C12N7/04 ,  C12N15/62 ,  C12N15/85 ,  C12N15/86

Abstract: Disclosed herein are recombinant adenoviruses with one or more nucleotide sequences inserted between two viral transcription units, formulations comprising the recombinant adenoviruses, and methods of treatment using the recombinant adenoviruses. In some embodiments, the one or more nucleotide sequences are inserted in an IX-E2 insertion site and/or an L5-E4 insertion site.

公开(公告)号：US12036247B2

公开(公告)日：2024-07-16

申请号：US16604675

申请日：2018-04-12

Applicant: EpicentRx, Inc.

Inventor： Tony R. Reid ,  Christopher Larson ,  Bryan T. Oronsky

IPC: A61P35/00 ,  A61K35/74 ,  A61K35/768 ,  A61K48/00 ,  C07K14/54 ,  C12N9/64 ,  C12N15/86 ,  C12N15/861

CPC classification number: A61K35/74 ,  A61K35/768 ,  A61K48/00 ,  A61P35/00 ,  C12N9/6454 ,  C12N15/86 ,  C12N15/861 ,  C07K2319/50 ,  C12N2710/10343 ,  C12Y304/21075

Abstract: The invention relates to a recombinant adenovirus comprising two or more therapeutic transgenes, e.g., two components of a heterodimeric cytokine, separated by a cleavable linker.

公开(公告)号：US20200223901A1

公开(公告)日：2020-07-16

申请号：US16651079

申请日：2018-09-27

Applicant: EpicentRx, Inc.

Inventor： Christopher Larson ,  Tony R. Reid ,  Bryan T. Oronsky

IPC: C07K14/715 ,  C07K14/54 ,  C12N15/62 ,  A61P35/00

Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., an IL-10 trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion protein, or an expression vector encoding for the fusion proteins, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

公开(公告)号：US20200032223A1

公开(公告)日：2020-01-30

申请号：US16604194

申请日：2018-04-10

Applicant: EpicentRx, Inc.

Inventor： Tony R. Reid ,  Bryan T. Oronsky ,  Christopher Larson

IPC: C12N7/00

Abstract: The invention relates to a method for producing a recombinant virus, e.g., a recombinant oncolytic adenovirus, using an A549 host cell.

公开(公告)号：US11834492B2

公开(公告)日：2023-12-05

申请号：US16651079

申请日：2018-09-27

Applicant: EpicentRx, Inc.

Inventor： Christopher Larson ,  Tony R. Reid ,  Bryan T. Oronsky

IPC: C07K14/715 ,  A61P35/00 ,  C07K14/54 ,  C12N15/62 ,  A61K38/00

CPC classification number: C07K14/7155 ,  A61P35/00 ,  C07K14/5428 ,  C12N15/62 ,  A61K38/00 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/50

Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., an IL-10 trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion protein, or an expression vector encoding for the fusion proteins, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

公开(公告)号：US20180134766A1

公开(公告)日：2018-05-17

申请号：US15717199

申请日：2017-09-27

Applicant: EpicentRx, Inc.

Inventor： Christopher Larson ,  Tony R. Reid ,  Bryan T. Oronsky

IPC: C07K14/71 ,  C07K16/00 ,  A61K35/768 ,  C12N7/00 ,  A61P35/00

CPC classification number: C07K14/71 ,  A61K35/768 ,  A61K38/00 ,  A61K48/00 ,  A61P35/00 ,  C07K16/00 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/53 ,  C07K2317/76 ,  C07K2319/01 ,  C07K2319/30 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/10332 ,  C12N2710/10333 ,  C12N2710/10343 ,  C12N2710/10371

Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., a TGFβ trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion proteins, or expression vectors encoding for the fusion proteins, e.g., oncolytic adenoviral expression vectors, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

公开(公告)号：US12295976B2

公开(公告)日：2025-05-13

申请号：US17042822

申请日：2019-03-28

Applicant: EpicentRx, Inc.

Inventor： Christopher Larson ,  Bryan T. Oronsky ,  Tony R. Reid

IPC: A61K35/761 ,  A61K38/16 ,  C12N15/10 ,  C12N15/861

Abstract: The invention provides for a recombinant adenoviral vector comprising a recombinant oncolytic adenovirus which has: (1) a modified transcription regulatory sequence wherein the adenoviral vector is transcriptionally active in cancer cells and/or hyperproliferative cells and transcriptionally attenuated in normal cells, and (2) a transgene encoding one or more cancer antigens that are specific to a subject. The invention further provides a method of producing said recombinant adenoviral vector. The recombinant oncolytic adenoviral vector described above is used in methods of stimulating a heightened immune response against a cancer antigen in a subject or a method of treating cancer in a subject.

公开(公告)号：US12054530B2

公开(公告)日：2024-08-06

申请号：US17150993

申请日：2021-01-15

Applicant: EpicentRx, Inc.

Inventor： Christopher Larson ,  Tony R. Reid ,  Bryan T. Oronsky

IPC: C07K14/71 ,  A61K35/768 ,  A61K38/00 ,  A61K48/00 ,  A61P35/00 ,  C07K16/00 ,  C12N7/00 ,  C12N15/86

CPC classification number: C07K14/71 ,  A61P35/00 ,  C07K16/00 ,  C12N7/00 ,  C12N15/86 ,  A61K35/768 ,  A61K38/00 ,  A61K48/00 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/53 ,  C07K2317/76 ,  C07K2319/01 ,  C07K2319/30 ,  C12N2710/10332 ,  C12N2710/10333 ,  C12N2710/10343 ,  C12N2710/10371

Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., a TGFβ trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion proteins, or expression vectors encoding for the fusion proteins, e.g., oncolytic adenoviral expression vectors, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.